Douglas R Strother1, Lucie Lafay-Cousin, James M Boyett, Peter Burger, Patricia Aronin, Louis Constine, Patricia Duffner, Mehmet Kocak, Larry E Kun, Marc E Horowitz, Amar Gajjar. 1. University of Calgary, Calgary, Canada (D.R.S., L.L.-C.); St Jude Children's Research Hospital, Memphis, Tennessee (J.M.B., L.E.K., A.G.); Johns Hopkins University, Baltimore, Maryland (P.B.); Dell Children's Medical Center of Central Texas, Austin, Texas (P.A.); University of Rochester, Rochester, New York (L.C.); (retired) Roswell Park Cancer Institute, Buffalo, New York (P.D.); University of Tennessee Health Science Center, Tennessee (M.K.); Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas (M.E.H.).
Abstract
BACKGROUND: The randomized controlled Pediatric Oncology Group study 9233 tested the hypothesis that dose-intensive (DI) chemotherapy would improve event-free survival (EFS) for children <3 years of age with newly diagnosed malignant brain tumors. METHODS: Of 328 enrolled eligible patients, diagnoses were medulloblastoma (n = 112), ependymoma (n = 82), supratentorial primitive neuroectodermal tumor (sPNET, n = 38) and other malignant brain tumors (n = 96), and were randomized to 72 weeks of standard dose chemotherapy (Regimen A, n = 162) or DI chemotherapy (Regimen B, n = 166). Radiation therapy (RT) was recommended for patients with evidence of disease at completion of chemotherapy or who relapsed within 6 months of chemotherapy completion. RESULTS: Distributions of EFS for Regimens A and B were not significantly different (P = 0.32) with 2- and 10-year rates of 22.8% ± 3.3% and 15.4% ± 3.7%, and 27.1% ± 3.4% and 20.8% ± 3.8%, respectively. Thus, the study hypothesis was rejected. While distributions of EFS and OS were not significantly different between Regimens A and B for patients with medulloblastoma and sPNET, DI chemotherapy resulted in significantly improved EFS distribution (P = .0011) (2-year EFS rates of 42.1% vs. 19.6% with SD chemotherapy), but not OS distribution, for patients with centrally confirmed ependymoma. The degree of surgical resection affected EFS, OS or both for most tumor groups. Approximately 20%, 40% and 20% of patients with medulloblastoma, ependymoma treated with DI chemotherapy, and sPNET, respectively appear to have been cured without RT. Of 11 toxic deaths on study, 10 occurred on the DI chemotherapy arm. CONCLUSIONS:Prolonged dose-intensive chemotherapy given to infants with malignant brain tumors resulted in increased EFS only for patients with ependymoma.
RCT Entities:
BACKGROUND: The randomized controlled Pediatric Oncology Group study 9233 tested the hypothesis that dose-intensive (DI) chemotherapy would improve event-free survival (EFS) for children <3 years of age with newly diagnosed malignant brain tumors. METHODS: Of 328 enrolled eligible patients, diagnoses were medulloblastoma (n = 112), ependymoma (n = 82), supratentorial primitive neuroectodermal tumor (sPNET, n = 38) and other malignant brain tumors (n = 96), and were randomized to 72 weeks of standard dose chemotherapy (Regimen A, n = 162) or DI chemotherapy (Regimen B, n = 166). Radiation therapy (RT) was recommended for patients with evidence of disease at completion of chemotherapy or who relapsed within 6 months of chemotherapy completion. RESULTS: Distributions of EFS for Regimens A and B were not significantly different (P = 0.32) with 2- and 10-year rates of 22.8% ± 3.3% and 15.4% ± 3.7%, and 27.1% ± 3.4% and 20.8% ± 3.8%, respectively. Thus, the study hypothesis was rejected. While distributions of EFS and OS were not significantly different between Regimens A and B for patients with medulloblastoma and sPNET, DI chemotherapy resulted in significantly improved EFS distribution (P = .0011) (2-year EFS rates of 42.1% vs. 19.6% with SD chemotherapy), but not OS distribution, for patients with centrally confirmed ependymoma. The degree of surgical resection affected EFS, OS or both for most tumor groups. Approximately 20%, 40% and 20% of patients with medulloblastoma, ependymoma treated with DI chemotherapy, and sPNET, respectively appear to have been cured without RT. Of 11 toxic deaths on study, 10 occurred on the DI chemotherapy arm. CONCLUSIONS: Prolonged dose-intensive chemotherapy given to infants with malignant brain tumors resulted in increased EFS only for patients with ependymoma.
Authors: P K Duffner; M E Horowitz; J P Krischer; P C Burger; M E Cohen; R A Sanford; H S Friedman; L E Kun Journal: Neuro Oncol Date: 1999-04 Impact factor: 12.300
Authors: J Russell Geyer; Richard Sposto; Mark Jennings; James M Boyett; Richard A Axtell; David Breiger; Emmett Broxson; Bernadine Donahue; Jonathan L Finlay; Joel W Goldwein; Linda A Heier; Dennis Johnson; Claire Mazewski; Douglas C Miller; Roger Packer; Diane Puccetti; Jerilynn Radcliffe; May Lin Tao; Tania Shiminski-Maher Journal: J Clin Oncol Date: 2005-10-20 Impact factor: 44.544
Authors: Stefan Rutkowski; Udo Bode; Frank Deinlein; Holger Ottensmeier; Monika Warmuth-Metz; Niels Soerensen; Norbert Graf; Angela Emser; Torsten Pietsch; Johannes E A Wolff; Rolf D Kortmann; Joachim Kuehl Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: P K Duffner; M E Horowitz; J P Krischer; H S Friedman; P C Burger; M E Cohen; R A Sanford; R K Mulhern; H E James; C R Freeman Journal: N Engl J Med Date: 1993-06-17 Impact factor: 91.245
Authors: Richard G Grundy; Sophie A Wilne; Claire L Weston; Kath Robinson; Linda S Lashford; James Ironside; Tim Cox; W Kling Chong; Richard H A Campbell; Cliff C Bailey; Rao Gattamaneni; Sue Picton; Nicky Thorpe; Conor Mallucci; Martin W English; Jonathan A G Punt; David A Walker; David W Ellison; David Machin Journal: Lancet Oncol Date: 2007-08 Impact factor: 41.316
Authors: Michal Zapotocky; Kiran Beera; Jenny Adamski; Normand Laperierre; Sharon Guger; Laura Janzen; Alvaro Lassaletta; Liana Figueiredo Nobre; Ute Bartels; Uri Tabori; Cynthia Hawkins; Stacey Urbach; Derek S Tsang; Peter B Dirks; Michael D Taylor; Eric Bouffet; Donald J Mabbott; Vijay Ramaswamy Journal: Cancer Date: 2019-02-15 Impact factor: 6.860
Authors: Alyssa T Reddy; Douglas R Strother; Alexander R Judkins; Peter C Burger; Ian F Pollack; Mark D Krailo; Allen B Buxton; Chris Williams-Hughes; Maryam Fouladi; Anita Mahajan; Thomas E Merchant; Ben Ho; Claire M Mazewski; Victor A Lewis; Amar Gajjar; Louis-Gilbert Vezina; Timothy N Booth; Kerry W Parsons; Vicky L Poss; Tianni Zhou; Jaclyn A Biegel; Annie Huang Journal: J Clin Oncol Date: 2020-02-27 Impact factor: 44.544
Authors: Thomas E Merchant; Anne E Bendel; Noah D Sabin; Peter C Burger; Dennis W Shaw; Eric Chang; Shengjie Wu; Tianni Zhou; David D Eisenstat; Nicholas K Foreman; Christine E Fuller; Edwina Templeton Anderson; Juliette Hukin; Ching C Lau; Ian F Pollack; Fred H Laningham; Robert H Lustig; Floyd D Armstrong; Michael H Handler; Chris Williams-Hughes; Sandra Kessel; Mehmet Kocak; David W Ellison; Vijay Ramaswamy Journal: J Clin Oncol Date: 2019-02-27 Impact factor: 44.544
Authors: Yuan Y Thompson; Vijay Ramaswamy; Phedias Diamandis; Craig Daniels; Michael D Taylor Journal: Childs Nerv Syst Date: 2015-09-09 Impact factor: 1.475
Authors: Juan C Espinoza; Kelley Haley; Neha Patel; Girish Dhall; Sharon Gardner; Jeffrey Allen; Joseph Torkildson; Albert Cornelius; Rod Rassekh; Antranik Bedros; Morris Etzl; James Garvin; Kamnesh Pradhan; Robin Corbett; Michael Sullivan; Geoffrey McGowage; Dagmar Stein; Rama Jasty; Stephen A Sands; Lingyun Ji; Richard Sposto; Jonathan L Finlay Journal: Pediatr Blood Cancer Date: 2016-06-22 Impact factor: 3.167